A single-centre, open-label, phase I trial evaluating the pharmacokinetics of single ascending oral doses of IRL757 in healthy elderly volunteers
This study is testing a new medicine called IRL757. It's a very early-stage trial, focusing on healthy older volunteers to understand how the body processes the medicine. This involves seeing how much of the medicine gets absorbed, how it moves around inside the body, and how quickly it's removed. By giving different doses, researchers can learn more about its effects. This information is important for potentially helping people who experience apathy, a condition where individuals lack motivation or interest, often linked to brain disorders. Taking part helps scientists develop new treatments in the future.
At a glance
What is this study about?
This study is focused on a new medicine called IRL757. It's what we call a 'Phase I' trial. This is one of the very first steps in testing a new medicine in people. The main goal here isn't to treat a specific illness yet, but to understand more about the medicine itself. Researchers want to see how the body reacts to IRL757 when healthy people take it. They'll be looking at things like how much of the medicine gets into the bloodstream, how long it stays there, and how the body breaks it down.
This particular study is looking at single doses of IRL757, meaning participants will take one dose at a time, and the researchers might increase the amount of the dose over time to see different effects. By doing this, they can figure out a safe range of doses and how the medicine behaves in the body. This information is really important for future studies that will look at whether IRL757 can actually help people with certain conditions.
The medicine is being developed with the aim of helping people who experience apathy. Apathy means a lack of interest, enthusiasm, or concern. It's a symptom that can sometimes happen in people with certain brain conditions. By understanding how IRL757 works in healthy people first, scientists can then move on to test if it can effectively and safely help those living with apathy.
Key takeaways
- This is a very early study of a new medicine called IRL757.
- It's for healthy older volunteers to understand how the medicine works in the body.
- The study aims to help people with apathy in the future.
- You will take single doses and be closely monitored by doctors.
- Participation helps future medical research develop new treatments.
Who may be eligible?
To join this study, you need to be a healthy older adult. This means that you don't have any major health problems that would make taking the study medicine unsafe or interfere with the results. Researchers want to make sure they are studying the medicine in people whose bodies are working normally.
Since this is an early study, they are trying to understand the medicine without other health conditions affecting how it works. Both men and women can take part in this study. The study is open to adults of all ages, though it specifically mentions 'elderly volunteers' so typically there would be an age cut-off, although it's not specified here.
Before you can join, you'll have some health checks to make sure you're suitable. These checks help the medical team make sure the study is safe for you and that the results they get will be clear and useful for future research.
- Am I a healthy older adult?
- Do I have any major ongoing health conditions?
- Am I comfortable taking a new medicine?
- Am I able to attend regular clinic visits?
- Am I willing to have blood tests?
This is a guide only — the research team will confirm whether you can take part.
What does participation involve?
If you decide to take part in this study, you'll be given a new medicine called IRL757. You'll take a single dose of this medicine, and you'll be carefully watched by the study team. You'll likely need to visit the study clinic several times. During these visits, the team will take blood samples to measure how much of the medicine is in your body and how long it stays there. They'll also check your general health, like your blood pressure and heart rate, to make sure you're doing well.
The total number of visits and the overall length of time you'll be involved in the study will depend on the specific details of the trial, but because it's a single-dose study, it typically involves a period of careful observation after taking the medicine, followed by some check-up visits. You'll have regular contact with the study team throughout your participation.
Potential risks and benefits
Locations (1)
- —Sweden
Common questions
What is apathy?
Apathy means a lack of interest, enthusiasm, or concern. It can be a symptom in people with certain brain conditions.
Is this medicine trying to cure apathy?
No, this early study is mainly about understanding how the new medicine works in the body, not yet about treating apathy directly. That would come in later studies.
Will I have to stay overnight?
The study details don't say if overnight stays are needed, but for early studies, it's common to have some extended stays for careful monitoring after taking the medicine.
What kind of tests will I have?
You'll likely have blood tests to check the medicine levels and general health checks like blood pressure and heart rate.
Will I be paid for taking part?
The study information doesn't mention payment, but some studies offer reimbursement for travel or time. You should ask the study team about this.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.